A, The number of patients with CHF analyzed per age group is given. P value is for analysis of variance test. B, CHIP-associated mutations in 56 analyzed genes that resulted in a variant allele fraction higher than 0.02 and remained positive after stringent unsupervised and supervised variant calling criteria are included. Because some patients carried more than 1 mutation, the total number of identified mutations leading to clonal expansion exceeds the number of patients with CHIP. The list of individual mutations can be found in eTable 3 in the Supplement.
A, Bubble size reflects the sample size of patients carrying each individual mutation, dashed line reflects incidence of death combined with rehospitalization for heart failure for patients who were not carriers of clonal hematopoiesis of indeterminate potential (CHIP). See eTable 1 in the Supplement for gene annotation. B, Overall survival of patients with DNMT3A or TET2 mutations with a variant allele fraction (VAF) of at least 0.02 vs non-CHIP patients. C, Event-free survival free of death or rehospitalization for heart failure with DNMT3A or TET2 mutations with a VAF of at least 0.02 vs non-CHIP patients. P values are for log-rank tests.
A, Overall survival of patients with DNMT3A or TET2 mutations with a VAF greater than 0.005 to 0.01; a VAF of at least 0.01 to 0.02; a VAF of at least 0.02; and non-CHIP patients reveals dose-response of clone size and clinical outcome; B, Event-free survival free of death or rehospitalization for heart failure with DNMT3A or TET2 mutations at various VAFs vs non-CHIP patients. P values are for log-rank tests.
eFigure. Patient Selection from the Individualized Parent Trials
eTable 1. List of Genes Analyzed by Custom TruSeq Targeted Sequencing Panel
eTable 2. CHIP-Associated Somatic Variants Identified in CHF Patients
eTable 3. Baseline Characteristics of TET2/DNMT3A-mutated and Non-CHIP CHF Patients
Customize your JAMA Network experience by selecting one or more topics from the list below.
Dorsheimer L, Assmus B, Rasper T, et al. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiol. 2019;4(1):25–33. doi:10.1001/jamacardio.2018.3965
What is the clinical significance of clonal hematopoiesis of indeterminate potential (CHIP) for chronic heart failure (CHF) owing to ischemic origin?
In this cohort study, CHIP had a high prevalence in 200 investigated patients with CHF. While no clinical baseline characteristics associated with CHF were different between CHIP carriers and non-CHIP carriers, except for the mean age, harboring mutations in the most prevalent driver genes associated with CHIP, namely DNMT3A and TET2, was associated with a significant and profound increase in death and rehospitalization for heart failure.
Clonal hematopoiesis of indeterminate potential is presented as a newly identified risk factor for impaired long-term survival and increased disease progression in patients with CHF that may be well targetable as a valuable approach to precision medicine in patients with CHF carrying specific mutations encoding for clonal hematopoiesis.
Somatic mutations causing clonal expansion of hematopoietic cells (clonal hematopoiesis of indeterminate potential [CHIP]) are increased with age and associated with atherosclerosis and inflammation. Age and inflammation are the major risk factors for heart failure, yet the association of CHIP with heart failure in humans is unknown.
To assess the potential prognostic significance of CHIP in patients with chronic heart failure (CHF) owing to ischemic origin.
Design, Setting, and Participants
We analyzed bone marrow–derived mononuclear cells from 200 patients with CHF by deep targeted amplicon sequencing to detect the presence of CHIP and associated such with long-term prognosis in patients with CHF at University Hospital Frankfurt, Frankfurt, Germany. Data were analyzed between October 2017 and April 2018.
Median age of the patients was 65 years. Forty-seven mutations with a variant allele fraction (VAF) of at least 0.02 were found in 38 of 200 patients with CHF (18.5%). The somatic mutations most commonly occurred in the genes DNMT3A (14 patients), TET2 (9 patients), KDM6A (4 patients), and BCOR (3 patients). Patients with CHIP were older and more frequently had a history of hypertension. During a median follow-up of 4.4 years, a total of 53 patients died, and 23 patients required hospitalization for heart failure. There was a significantly worse long-term clinical outcome for patients with either DNMT3A or TET2 mutations compared with non-CHIP carriers. By multivariable Cox proportional regression analysis, the presence of somatic mutations within TET2 or DNMT3A (HR, 2.1; 95% CI, 1.1-4.0; P = .02, for death combined with heart failure hospitalization) and age (HR, 1.04; 95% CI, 1.01-1.07 per year; P = .005) but not a history of hypertension remained independently associated with adverse outcome. Importantly, there was a significant dose-response association between VAF and clinical outcome.
Conclusions and Relevance
Our data suggest that somatic mutations in hematopoietic cells, specifically in the most commonly mutated CHIP driver genes TET2 and DNMT3A, may be significantly associated with the progression and poor prognosis of CHF. Future studies will have to validate our findings in larger cohorts and address whether targeting specific inflammatory pathways may be valuable for precision medicine in patients with CHF carrying specific mutations encoding for CHIP.
Quiz Ref IDClonal hematopoiesis of indeterminate potential (CHIP) is defined as the presence of an expanded somatic blood cell clone in persons without other hematological abnormalities.1-3 The presence of CHIP was shown to increase with age and is significantly associated with the risk for coronary heart disease.2,4Quiz Ref ID The most commonly mutated genes in CHIP are the DNA methyltransferase DNMT3A and the DNA demethylase TET2, which both epigenetically control gene expression. Functionally, these 2 predominant CHIP driver genes are important regulators of inflammation by augmenting monocyte adhesion and stimulated macrophage activity.5,6 Accordingly, loss of TET2 function in hematopoietic cells accelerates atherosclerosis and promotes inflammasome activation in mice,4,7 whereas loss of DNMT3A experimentally altered myeloid cell function and promoted upregulation of chemokines.8,9
Aging is the major risk factor for heart failure,10 and inflammation importantly contributes to the progression of ischemic heart failure.11 However, to our knowledge, there are no data assessing the incidence and potential prognostic significance of the presence of CHIP in patients with chronic heart failure (CHF) owing to ischemic origin. Therefore, we used targeted amplicon sequencing to detect the presence of CHIP in bone marrow–derived mononuclear cells (BMC) and associated such presence with long-term prognosis in patients with chronic ischemic heart failure.
Clinical data and biological specimens (BMC) were collected from a total of 200 patients with CHF and participating in different trials examining the effects of intracoronary administration of autologous BMCs between June 2005 and July 2017 at the University Hospital of the Goethe University, Frankfurt/Main, Germany. All patients provided written informed consent for 1 of the following registered clinical trials: Transplantation of Progenitor Cells and Recovery of Left Ventricular Function in Patients with Chronic Ischemic Heart Disease (TOPCARE-CHD; Crossover or Registry; n = 134; NCT00289822 or NCT0096236412,13), Cellwave (n = 55; NCT0032698914) or Repetitive Progenitor Cell Therapy in Advanced Chronic Heart Failure (REPEAT; n = 11; NCT0169304213). The selection of patients from the individual parent trials is illustrated in the eFigure in the Supplement. In addition to the clinical trials, patients provided additional informed consent for genetic testing of bone marrow samples. The ethics review board of the Goethe University in Frankfurt, Germany, approved the protocols. The study complies with the Declaration of Helsinki. Patients were eligible for inclusion into the study if they had stable CHF symptoms New York Heart Association (NYHA) classification of at least II, had a previous successfully revascularized myocardial infarction at least 3 months before bone marrow aspiration, and had a well-demarcated region of left ventricular dysfunction on echocardiography. Exclusion criteria were the presence of acutely decompensated heart failure with NYHA class IV, an acute ischemic event within 3 months prior to inclusion, a history of severe chronic diseases, documented cancer within the preceding 5 years, or unwillingness to participate.
Clinical data, medication, and laboratory data were prospectively collected. Follow-up visits were scheduled at 3 to 4 months after cell application and at 12 months after cell application and were performed by physicians, whereas follow-up telephone calls were performed by study nurses at 18, 24, 36, and 48 months. The Seattle Heart Failure Model (SHFM) score was calculated by including age, sex, etiology of cardiomyopathy (ischemic origin), heart rate, systolic blood pressure, ejection fraction, medication (angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, aldosterone blocker, β-blocker, statins, diuretic type and daily dose, and allopurinol), and laboratory values (serum sodium, total cholesterol, hemoglobin, percent lymphocytes, and uric acid). In addition, the presence of any implantable device (pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy) is included into the calculation of the SHFM Score. N-terminal pro b-type natriuretic peptide (NT-proBNP) serum levels were measured at the time of bone marrow harvest.
Mortality and mode of death were adjudicated by means of reviewing medical records by the study physicians. Mode of death was classified as sudden death (unexpected death in a clinically stable patient, typically within 1 hour of symptom onset, from documented or presumed cardiac arrhythmia and without a clear noncardiovascular cause), pump failure (progressively reduced cardiac output and failure of organ perfusion), noncardiac death, or not classifiable. Missing data on survival were obtained by contacting the federal registration offices. Rehospitalization for heart failure was defined as an at least 24 hours’ hospital stay for heart failure symptoms with documented change in heart failure–directed medication. Physicians assessing heart failure admissions were unaware of the mutation status of the patients.
Bone marrow aspirate (50 mL) was obtained from the iliac crest with local anesthesia. Bone marrow–derived mononuclear cells were isolated by Ficoll density-gradient centrifugation, as previously reported.12,15
DNA was isolated with QIAamp DNA Mini Kit (Qiagen) from deep-frozen samples of BMC and peripheral blood. The concentration of the extracted genomic DNA was determined using the Qubit dsDNA HS Assay Kit (Life Technologies) on a Qubit Fluorometer (Life Technologies).
A custom panel based on the Illumina TruSeq Custom Amplicon Low Input assay was designed to assess the presence of CHIP in the patients. The panel includes 594 amplicons in 56 genes (eTable 1 in the Supplement) commonly mutated in CHIP and myeloid malignancies. To allow improved identification of low allele frequency variants, a dual-strand approach was used. In addition, 6-bp unique molecular identifiers (UMIs) were included in the target specific primers.
Target enrichment was performed from 40-ng genomic DNA according to the instructions of the TruSeq Custom Amplicon Low Input Kit (Illumina). The hybridization of the oligo pool to the target regions, the extension from the upstream oligo, and the following ligation to the 5′ end of the downstream oligo was performed on a T100 Thermal Cycler (Bio-Rad Laboratories). Amplification of the ligation products and addition of the Illumina i7 and i5 adapter sequences was performed on a T100 Thermal Cycler (Bio-Rad Laboratories). After purification, library quality and size distribution were assessed on a Bioanalyzer 2100 (Agilent Technologies) using the DNA 1000 Kit. Bead-based library normalization was performed before pooling of the individual libraries.
Before sequencing, the pooled libraries were diluted and denatured according to the NextSeq System Denature and Dilute Libraries Guide (Illumina) and 1% PhiX DNA was added. The pooled libraries were sequenced on a NextSeq 500 sequencer (Illumina) using the NextSeq 500/550 Mid Output, version 2 kit (300 cycles) according to the manufacturer’s instructions. The sequencer was operated in a paired-end sequencing mode with 2 × 150 bp read length and 2 × 8 bp index read length. The BCL files were demultiplexed and converted to FASTQ files using the FASTQ Generation tool on BaseSpace (Illumina). The median coverage across all BMC samples was 4282× before UMI family clustering and 630× with inclusion of UMIs.
Read quality was assessed using FastQC.16 FASTQ files from each patient were merged and reads were grouped into unique molecular identifier (UMI) families using the UMI-tools software package.17 Reads were mapped to the hg19 draft of the human genome using Burrows-Wheeler Alignment–MEM. The `dedup` command of the UMI-tools software package was used to remove polymerase chain reaction duplicates with the same UMIs and alignment coordinates. Variant calling was performed using FreeBayes18 without allele frequency threshold, a minimum alternate read count of 2, and a minimum base and mapping quality of 20. Variant effect prediction and variant annotation was performed using SnpEff and SnpSift.19
The identified variants were processed and filtered using the R programming language, version 3.3.1 (R Programming). Common single-nucleotide polymorphisms with a minor allele frequency of at least 5% in either the 1000 Genome Project, Exome Variant Server, or ExAC databases were excluded. In addition, variants with a low mapping quality (<20) and variants occurring in 8% or more of the patients in the studied cohort were considered as technical artifacts and excluded. Furthermore, variants covered with fewer than 100 reads in at least 1 set of amplicons (CAT A or CAT B), variants called with only 1 of the set of amplicons (CAT A or CAT B), single-nucleotide polymorphisms identified as common in the single-nucleotide polymorphism database (≥1% in the human population), and variants with sequence ontology terms “LOW” or “MODIFIER” were filtered out. According to previously established definitions,3 all variants with a variant allele fraction (VAF) of at least 0.02 (2%) were considered; VAF was calculated by using the formula VAF = alternate reads / (reference + alternate reads). Variants with a VAF of 0.45 to 0.55 were not considered to exclude potential germline variants.
The variants were further validated on the basis of being reported in the literature and/or the Catalogue of Somatic Mutations in Cancer (https://cancer.sanger.ac.uk/cosmic) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar).
Continuous variables are presented as mean (SD), and as median (interquartile range [IQR]) unless otherwise noted. Analysis of variance testing was used for comparison of continuous variables between groups. Categorical variables were compared with the χ2 test or Fisher exact test as appropriate.
For survival analysis within the individual groups, Kaplan-Meier analyses were used. Log rank testing was applied for comparison of event-free survival analysis. In addition, a multivariable Cox proportional-hazards regression model was used to calculate hazard ratios (HRs) for event rates, using the univariate significant factors associated with adverse outcome, namely age and a history of hypertension, as covariates. In addition, to comprehensively adjust for potentially confounding prognostic factors in CHF, a multivariate stepwise Cox regression analysis was performed including baseline serum NT-proBNP levels (stepwise approach using steps of 1000 pg/mL [to convert to nanograms per liter, multiply by 1]) as well as the SHFM score tertiles. Statistical significance was assumed at P less than .05, and all reported P values are 2-sided. Statistical analysis was performed with SPSS, version 23.0 (SPSS Inc).
To examine whether CHIP plays a potential role in CHF, we analyzed BMCs from 200 patients with CHF by targeted amplicon sequencing of 56 genes associated with CHIP and myeloid malignancies (eTable 1 in the Supplement). Patients had a median age of 65 years, NYHA class II, and a left ventricular ejection fraction of 31% owing to a previous myocardial infarction (median time since last infarction, 5 years; Table 1). Median time of follow-up was 4.4 years (IQR, 2.8-5).
Thirty-eight of 200 patients with CHF (18.5%) were CHIP carriers with a VAF of at least 0.02. Consistent with previous findings in the general population,2 the prevalence of CHIP in the present cohort of patients with CHF of ischemic origin increased with patient age (Figure 1A). However, compared with published cohorts of unselected populations2 as well as patients with coronary heart disease,4 the frequency of identified mutations was considerably higher in all age groups, with 10% of patients between age 50 and 59 years (5 of 50), 20.9% between age 60 and 69 years (14 of 67 patients), and 26.6% between age 70 and 79 years (17 of 64 patients) harboring CHIP-related mutations (Figure 1A). Thus, CHIP was enriched in patients with CHF of ischemic origin.
Forty-seven different somatic mutations with a VAF of at least 0.02 were identified (eTable 2 in the Supplement). The somatic mutations most commonly occurred in the genes DNMT3A (14 patients), TET2 (9 patients), KDM6A (4 patients), and BCOR (3 patients) followed by ASXL, CBLC, SF3B1, and TP53 (2 patients each). Nine other genes associated with CHIP were found to be mutated in individual patients (Figure 1B). Thirty of 38 participants (79%) with CHIP had a mutation in only a single driver gene, whereas 2 mutations were identified in 7 patients, and 1 patient even exhibited 3 mutations. The mean VAF was 0.065 (range, 0.02-0.23), which corresponds to 13.0% of nucleated blood cells harboring the mutation at the time of analysis, assuming all are heterozygous mutations.
In patients with DNMT3A and TET2 mutations in their BMCs, we also verified the presence of the respective CHIP driver gene mutation in samples of peripheral blood cells obtained at the time of bone marrow harvest. In all these patients, we also detected the respective mutation in peripheral blood cells with a close association in VAF between bone marrow–derived and blood-derived cells (r = 0.81; P = .001).
Table 1 summarizes the baseline characteristics of CHIP and non-CHIP carriers in our cohort of patients with CHF. There were no significant differences except that CHIP carriers were significantly older and more frequently had a history of hypertension than non-CHIP carriers. Except for arterial hypertension, the classic cardiovascular risk factors, such as hyperlipidemia, diabetes mellitus, family history of coronary artery disease, and smoking habits, were not different between CHIP and non-CHIP carriers in our cohort. Likewise, the extent of coronary artery disease was not statistically significantly different between CHIP and non-CHIP patients.
Most importantly, baseline NYHA class, left ventricular ejection fraction, and NT-proBNP serum levels as well as the SHFM score did not differ between the 2 groups (Table 1). Taken together, in patients with CHF owing to ischemic origin, CHIP carriers did not differ from non-CHIP carriers with respect to clinical parameters of heart function and disease stage.
During a median follow-up of 4.4. years, a total of 53 patients died, and 23 patients required hospitalization for heart failure. Thirty-nine of 162 patients (24%) without CHIP and 14 of 38 (37%) with CHIP died during follow-up. Figure 2A graphically illustrates the relative incidence of death and rehospitalization for heart failure for CHIP carriers with respect to the presence of individual driver gene mutations. The size of the bubbles reflects the sample size of patients carrying each individual mutation. Because most CHIP driver mutations were mutations in DNMT3A and TET2, as also previously published for atherosclerosis,4 and experimental studies demonstrated that those mutations promote cardiac dysfunction in murine models of heart failure,8,9 we focused our subsequent analyses on these patients. Patients harboring either DNMT3A or TET2 mutations did not differ from non-CHIP carriers with respect to baseline clinical characteristics, pharmacologic treatment, or device therapy (eTable 3 in the Supplement). However, Kaplan-Meier event-free survival analyses documented a significantly worse long-term clinical outcome for both death (Figure 2B) and death combined with rehospitalization for heart failure (Figure 2C) for patients with CHF of ischemic origin harboring either DNMT3A or TET2 mutations in their bone marrow cells compared with non-CHIP carriers. In patients harboring DNMT3A or TET2 mutations, most deaths (6 of 11) were owing to progression of heart failure and arrhythmia, but there was only 1 death attributed to acute myocardial infarction, and no stroke-related death was observed.
Because age is a major driver of both the presence of CHIP as well as increased risk, stepwise multivariate Cox proportional regression analyses were performed to account for the significant baseline differences. As summarized in Table 2, the presence of somatic mutations within TET2 or DNMT3A remained independently associated with adverse outcome (death or death combined with heart failure hospitalization) in addition to age, whereas hypertension was not independently associated in this multivariable model. Finally, by multivariate Cox proportional regression analysis, including the SHFM score (as tertiles) as well as NT-proBNP serum levels at baseline (stepwise approach using steps of 1000 pg/mL), death as well as the combined event of death and rehospitalization for heart failure also remained independently associated with the presence of TET2 or DNMT3A mutations (death, HR, 3.25; 95% CI, 1.62-6.52; death combined with rehospitalization for heart failure, HR, 3.25; 95% CI, 1.71-6.19), in addition to SHFM score tertiles (death, tertile 2, HR, 6.6; 95% CI, 1.49-29.44 and tertile 3, HR, 26.47; 95% CI, 6.21-112.9) and NT-proBNP serum levels (death, HR, 1.06; 95% CI, 1.00-1.12 per 1000 pg/mL; death combined with rehospitalization for heart failure, HR, 1.11; 95% CI, 1.05-1.17). However, given the limited number of events in the patient cohort as well as the lack of standardized, generally acknowledged stepwise increases in NT-proBNP serum levels or SHFM score values, the HRs should be compared cautiously with the binary yes or no status for the CHIP-associated hazard ratio.
To assess a potential association between the extent of clonal expansion caused by DNMT3A and TET2 mutations and clinical outcome, we lowered the threshold of mutation calling to a VAF greater than 0.005. We found 66 additional DNMT3A and 53 additional TET2-mutated clones with a VAF between 0.005 and less than 0.02 affecting 69 patients. This result confirms a high penetrance of CHIP at low clonal size. To correlate the dosage of clonal expansion with clinical outcome in our patient cohort, we analyzed event-free Kaplan-Meier survival curves for patients with a VAF greater than 0.005 to 0.01; a VAF of at least 0.01 to 0.02; and a VAF of at least 0.02. As illustrated in Figure 3, there was a statistically significant dose-response association between clone size and clinical outcome. These data suggest that there might indeed be a causal association between DNMT3A and TET2 CHIP driver mutations and clinical outcome in patients with CHF.
The results of this study demonstrate that somatic mutations driving clonal hematopoiesis are frequent in patients with chronic ischemic heart failure and the most commonly mutated CHIP driver genes DNMT3A and TET2 are associated with profoundly impaired long-term survival and significantly increased disease progression in patients with CHF of ischemic origin.
While previous studies have documented a significant association of the presence of CHIP with the risk of coronary heart disease in humans,4 to our knowledge, this study is the first to show that somatic mutations driving clonal hematopoiesis are associated with profoundly impaired long-term survival and significantly increased disease progression in patients with CHF of ischemic origin. Consistent with previous studies, the most commonly mutated genes in this study were the DNA methyltransferase DNMT3A and the DNA demethylase TET2. The prevalence of CHIP appears to be significantly higher in the study cohort compared with previously published data in age-matched healthy participants2 or patients with coronary artery disease.4Quiz Ref ID Indeed, experimental studies8,9 disclosed that both TET2 and DNMT3A loss-of-function in murine hematopoietic stem cells promote cardiac dysfunction in murine models of heart failure.8,9 Taken together, these findings suggest that CHIP, at least mediated by mutations in the most prevalent driver genes DNMT3A and TET2, may contribute to the development of CHF in patients after myocardial infarction.
Quiz Ref IDHowever, more importantly, this study shows that patients with established CHF harboring mutations in TET2 or DNMT3A demonstrated a profoundly increased mortality during long term follow-up. The increased mortality was mainly driven by a progression of heart failure, but not by the occurrence of acute ischemic events, because only 1 death was owing to a recurring acute myocardial infarction. In addition, impaired clinical outcome associated with DNMT3A and TET2 CHIP driver mutations was independent of the classical prognostic factors SHFM score and NT-proBNP serum levels, which are regarded as the most comprehensive markers of clinical outcome in CHF. Instead, there was a dose-response association between clone size and worse clinical outcome, suggesting that the presence of DNMT3A or TET2 mutations indeed may causally contribute to disease progression in patients with chronic ischemic heart failure. Experimental studies have convincingly demonstrated that mice lacking hematopoietic TET2 are characterized by augmented IL-1β and inflammasome activation driving atherosclerosis and cardiac dysfunction in murine models of heart failure.4,7,9 Moreover, patients with TET2 clonal hematopoiesis have significantly elevated plasma levels of interleukin-8, the prototypical inflammatory chemokine in humans mediating monocyte adhesion to inflamed endothelium.4,20 Likewise, hematopoietic cell deficiency of DNMT3A in mice was in 2018 shown to promote inflammation via upregulation of specific cytokines and chemokines in stimulated macrophages.8Quiz Ref ID Because IL-1β neutralizing antibody treatment with canakinumab was shown in 2017 to reduce adverse cardiovascular events in patients with stable coronary heart disease (Cantos Trial),21 IL-1β neutralizing antibodies or broader inflammasome inhibitors may provide a targeted therapy for patients with CHF carrying mutations in TET2 and DNMT3A. Thus, although our study cannot provide a definitive causal relationship between the presence of clonal hematopoiesis and the significantly worse prognosis in patients with CHF, it is tempting to speculate that at least CHIP owing to mutations in the most prevalent driver genes TET2 and DNMT3A may be a modifiable risk factor for death in CHF. Additionally, experimental studies reported that TET2 can be activated by antioxidants such as vitamin C.22,23 Therefore, such strategies may also be considered for a targeted therapy augmenting the activity of the remaining wild-type TET2.
Nevertheless, clonal hematopoiesis may also contribute to the progression of heart failure by other mechanisms, including the release of different cardiokines and augmented senescence of BMCs by dysregulation of epigenetic modifiers, stimulation of myofibroblast generation by altered BMCs leading to increased cardiac fibrosis, and altered immunosurveillance. Future studies will have to address the specific mechanisms involved in the progression of heart failure in the presence of clonal hematopoiesis. Likewise, while the presence of CHIP was originally defined as the occurrence of mutations with a VAF of at least 0.02, the results of this study as well as data published in 2018 in healthy patients24 indicate that even lower VAFs may confer a survival disadvantage. Further studies are required to potentially identify a specific threshold for variant allele frequency in patients with CHF. However, to make this study comparable with previously published data regarding the role of CHIP in patients with cardiovascular disease, we did limit our conclusions to those patients fulfilling the original classical criteria for CHIP with a VAF of 0.02. The rare occurrence of numerous CHIP driver mutations other than DNMT3A and TET2 in mostly singular patients prevented an assessment of these mutations with respect to clinical outcome. Finally, because the patients studied are not a consecutive series of patients and the sample size is rather moderate, further studies will have to validate our findings in larger cohorts of patients with heart failure. Likewise, the limited number of events precludes the assessment of a potentially added prognostic value of measuring CHIP in addition to NT-proBNP serum levels or the SHFM score in patients with CHF. As such, the calculated respective HRs for the individual prognostic factors should be interpreted with caution.
In conclusion, our data support the hypothesis that somatic mutations in hematopoietic cells, specifically in the most commonly mutated CHIP driver genes TET2 and DNMT3A, may be significantly associated with the progression and poor prognosis of CHF of ischemic origin. Future studies will have to validate our findings in larger cohorts and to address whether targeting specific inflammatory pathways may be a valuable approach to precision medicine in patients with CHF carrying specific mutations encoding for clonal hematopoiesis.
Corresponding Author: Andreas M. Zeiher, MD, Department of Medicine III, Cardiology/Angiology/Nephrology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany (firstname.lastname@example.org).
Accepted for Publication: October 8, 2018.
Published Online: December 19, 2018. doi:10.1001/jamacardio.2018.3965
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Dorsheimer L et al. JAMA Cardiology.
Author Contributions: Drs Zeiher and Rieger had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Ms Dorsheimer and Dr Assmus contributed equally as first authors. Drs Dimmeler, Zeiher, and Rieger contributed equally as last authors.
Concept and design: Ortmann, Serve, Dimmeler, Zeiher, Rieger.
Acquisition, analysis, or interpretation of data: Dorsheimer, Assmus, Rasper, Ecke, Abou-El-Ardat, Schmid, Brune, Wagner, Serve, Hoffmann, Seeger, Zeiher, Rieger.
Drafting of the manuscript: Assmus, Zeiher, Rieger.
Critical revision of the manuscript for important intellectual content: Dorsheimer, Rasper, Ortmann, Ecke, Abou-El-Ardat, Schmid, Brune, Wagner, Serve, Hoffmann, Seeger, Dimmeler, Zeiher.
Statistical analysis: Assmus, Ecke, Abou-El-Ardat, Wagner.
Obtained funding: Serve, Dimmeler, Zeiher, Rieger.
Administrative, technical, or material support: Dorsheimer, Rasper, Ortmann, Schmid, Brune, Wagner, Serve, Hoffmann, Seeger.
Supervision: Dorsheimer, Wagner, Serve, Zeiher, Rieger.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Assmus reported personal fees from Novartis, Vifor, Boehringer, and Bayer and grants and personal fees from Abbott outside the submitted work. Dr Serve reported grants from German Cancer Consortium during the conduct of the study. Dr Dimmeler reported grants from BMBF/DZHK during the conduct of the study. Dr. Zeiher reported grants from German Research Foundation and grants from BMBF during the conduct of the study; personal fees from Sanofi, Pfizer, Amgen, and Boehringer Ingelheim; and other fees from T2cure outside the submitted work. Dr Rieger reported grants from Deutsche Forschungsgemeinschaft during the conduct of the study. No other disclosures were reported.
Funding/Support: The study was supported by the German Research Foundation (SFB 834; project B6 to Drs Assmus, Hoffmann, and Zeiher and Z1 to Ms Dorsheimer and Dr Rieger), the Excellence Cluster Cardiopulmonary Systems, project RI2462/1–1 (Dr Rieger), and by the German Center for Cardiovascular Research, Berlin, Germany, partner site Frankfurt Rhine-Main.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Marga Müller-Ardogan, RN, Department of Cardiology, University of Frankfurt, Frankfurt, Germany for excellent technical support and patient care.
Create a personal account or sign in to: